Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Exelixis
Neonc Technologies, Inc.
Bristol-Myers Squibb
Myeloid Therapeutics
Genentech, Inc.
ImmunityBio, Inc.
Mayo Clinic
Incyte Corporation
Bristol-Myers Squibb
Sarcoma Oncology Research Center, LLC
Molecular Templates, Inc.
University Hospital, Ghent
Gritstone bio, Inc.
Tempest Therapeutics
Fate Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
Nektar Therapeutics
Incyte Corporation
Duke University
Genocea Biosciences, Inc.
MultiVir, Inc.